Source: Annual Congress 2010 - Treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. S. Kim, B. K. Yoon, I. J. Oh, Y. C. Kim, Y. S. Kwon, Y. I. Kim, S. C. Lim, J. H. Lim, J. P. Jeong, H. J. Ban, S. Y. Chi, C. M. Park (Gwangju, , Suncheon, Republic Of Korea). Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines. Eur Respir J 2010; 36: Suppl. 54, 368

Member's Comments

No comment yet.

Related content which might interest you: Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models Source: Annual Congress 2010 - New insights in the pathology of lung cancer Year: 2010 EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017 Year: 2017 Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020 The inhibitory effect of PI3k inhibitor and MEK inhibitor on malignant pleural mesothelioma cell growth Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009 Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease Source: Eur Respir Rev, 26 (146) 170061; 10.1183/16000617.0061-2017 Year: 2017 Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib? Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009 Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009 Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012 Antitumor activity of MEK and PI3K inhibitors in malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019